Porter R J, Layzer R B
Arch Neurol. 1975 May;32(5):298-303. doi: 10.1001/archneur.1975.00490470042005.
The plasma protein binding of diphenylhydantoin sodium was determined in 26 patients who had been taking diphenylhydantoin regularly for more than two weeks. The free (unbound) diphenylhydantoin level was found to vary from 5.8% to 12.6% of the total drug concentration. This range of variation may be clinically important, if it can be established that the binding of diphenylhydantoin to plasma proteins limits entry of the drug into the brain. The binding of diphenylhydantoin was directly proportional to the plasma albumin concentration, which thus appeared to be the most important determinant of diphenylhydantoin binding. Diphenylhydantoin binding was independent of the plasma concentration of the drug in the usual therapeutic range. In vitro studies showed little effect by phenobarbital sodium or penicillin G; therapeutic levels of acetylsalicylic acid, however, increased free diphenylhydantoin by nearly 50%.
对26例连续服用苯妥英钠超过两周的患者测定了苯妥英钠的血浆蛋白结合率。结果发现,游离(未结合)苯妥英水平占总药物浓度的5.8%至12.6%。如果能够证实苯妥英与血浆蛋白的结合会限制药物进入大脑,那么这种变化范围可能具有临床意义。苯妥英的结合与血浆白蛋白浓度直接相关,因此血浆白蛋白似乎是苯妥英结合的最重要决定因素。在通常的治疗范围内,苯妥英的结合与药物的血浆浓度无关。体外研究表明,苯巴比妥钠或青霉素G影响很小;然而,治疗剂量的阿司匹林可使游离苯妥英增加近50%。